Literature DB >> 2938731

Increased thymidylate synthase in L1210 cells possessing acquired resistance to N10-propargyl-5,8-dideazafolic acid (CB3717): development, characterization, and cross-resistance studies.

A L Jackman, D L Alison, A H Calvert, K R Harrap.   

Abstract

The properties are described of a mutant L1210 cell line (L1210:C15) with acquired resistance (greater than 200-fold) to the thymidylate synthase (TS) inhibitor N10-propargyl-5,8-dideazafolic acid. TS was overproduced 45-fold and was accompanied by a small increase in the activity of dihydrofolate reductase (2.6-fold). Both the level of resistance and enzyme activities were maintained in drug-free medium (greater than 300 generations). Failure of N10-propargyl-5,8-dideazafolic acid to suppress the [3H]-2'-deoxyuridine incorporation into the acid-precipitable material of the resistant line supported the evidence that TS overproduction was the mechanism of resistance; consequently the L1210:C15 cells were largely cross-resistant to another (but weaker) TS inhibitor, 5,8-dideazafolic acid. Minimal cross-resistance was observed to the dihydrofolate reductase inhibitors methotrexate and 5-methyl-5,8-dideazaaminopterin (5- and 2-fold, respectively). L1210 and L1210:C15 cells were, however, equally sensitive to 5-fluorodeoxyuridine (FdUrd), an unexpected finding since a metabolite, 5-fluorodeoxyuridine monophosphate, is a potent TS inhibitor; however, this cytotoxicity against the L1210:C15 cells was antagonized by coincubation with 5 microM folinic acid although folinic acid potentiated the cytotoxicity of FdUrd to the N10-propargyl-5,8-dideazafolic acid-sensitive L1210 line. Thymidine was much less effective as a FdUrd protecting agent in the L1210:C15 when compared with the L1210 cells; however, a combination of thymidine plus hypoxanthine was without any additional effect (compared with thymidine alone) against the sensitive line but effectively protected L1210:C15 cells such that the concentration of FdUrd necessary to reduce the cell count to 50% of control at 48 h was increased greater than 11,000-fold. We propose that the elevated TS levels result in sequestration of the reduced-folate pool (as N5,10-methylene tetrahydrofolic acid) into the TS ternary complex with 5-fluoro-2'-deoxyuridine 5'-monophosphate. Despite "free" TS, the de novo synthesis of thymidylate and purines is inhibited by substrate depletion. The fact that folinic acid is able to reverse the inhibition of [3H]-2'-deoxyuridine incorporation by FdUrd into the resistant cells supports this hypothesis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2938731

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

1.  A human leukemia cell line made resistant to two folate analogues, trimetrexate and N10-propargyl-5,8-dideazafolic acid (CB3717).

Authors:  Y Takemura; T Ohnuma; H Miyachi; S Sekiguchi
Journal:  J Cancer Res Clin Oncol       Date:  1991       Impact factor: 4.553

2.  Amplification of the thymidylate synthase gene in an N10-propargyl-5,8-dideazafolic-acid-resistant human leukemia, MOLT-3 cell line developed in pteroylglutamic acid, but not in leucovorin.

Authors:  H Miyachi; Y Takemura; H Kobayashi; Y Ando
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 3.  Biological and biochemical properties of new anticancer folate antagonists.

Authors:  D W Fry; R C Jackson
Journal:  Cancer Metastasis Rev       Date:  1987       Impact factor: 9.264

4.  Cellular pharmacokinetics of ZD1694 in cultured human leukaemia cells sensitive, or made resistant, to this drug.

Authors:  Y Takemura; W Gibson; R Kimbell; H Kobayashi; H Miyachi; A L Jackman
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 5.  Standing the test of time: targeting thymidylate biosynthesis in cancer therapy.

Authors:  Peter M Wilson; Peter V Danenberg; Patrick G Johnston; Heinz-Josef Lenz; Robert D Ladner
Journal:  Nat Rev Clin Oncol       Date:  2014-04-15       Impact factor: 66.675

6.  Moderate antiproliferative effect of the antifolate CB3717 in the BN myeloid leukaemia model.

Authors:  A A Ermens; J Lindemans; J Abels
Journal:  Br J Cancer       Date:  1988-04       Impact factor: 7.640

7.  Deoxyuridine triphosphatase (dUTPase) expression and sensitivity to the thymidylate synthase (TS) inhibitor ZD9331.

Authors:  S D Webley; A Hardcastle; R D Ladner; A L Jackman; G W Aherne
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

8.  A novel class of lipophilic quinazoline-based folic acid analogues: cytotoxic agents with a folate-independent locus.

Authors:  L A Skelton; M G Ormerod; J Titley; R Kimbell; L A Brunton; A L Jackman
Journal:  Br J Cancer       Date:  1999-04       Impact factor: 7.640

9.  In vitro antitumour activity of cis- and trans-5-fluoro-5,6-dihydro-6-alkoxy-uracils; effects on thymidylate synthesis.

Authors:  C L van der Wilt; G W Visser; B J Braakhuis; R Wedzinga; P Noordhuis; K Smid; G J Peters
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

10.  Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines.

Authors:  A L Jackman; L R Kelland; R Kimbell; M Brown; W Gibson; G W Aherne; A Hardcastle; F T Boyle
Journal:  Br J Cancer       Date:  1995-05       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.